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Outdated dermatologic drug samples and obligations
to the patient
Jordan Wang, MBE, and Matthew Keller, MD
Philadelphia, Pennsylvania
CASE SCENARIO
A 37-year-old man with a slightly raised, red, scaly patch on his left arm is seen in the clinic of an
academic teaching hospital by a young dermatologist. Following examination and biopsy, he is found to
have squamous cell carcinoma in situ. The patient was recently laid off fromwork and had lost access to
his health insurance. He is struggling to make ends meet for his family, so it would be difficult for him to
cover any extraneous health-related expenses. Upon relaying this information to the dermatologist, the
patient is provided with a full course of 5-fluorouracil (topical cream 5%) from the clinic’s sample
cabinet. Later in the day, it is discovered that the same batch of drugs has been outdated for more than 4
months. Because the dermatologist was only recently hired, she worries that she will be severely
reprimanded for her failure to inspect the expiry date.
The dermatologist should:
A. Not do anything because the drug sample was only recently outdated, and the risk for adverse
outcomes may be considered to be relatively low.
B. Report the incident to a more senior dermatologist right away, and let that person ameliorate the
situation.
C. Call the patient as soon as possible to warn him of possible dangers of using outdated drugs, and
offer prompt exchange for a new sample.
D. Inform the patient of the potential risks associated with outdated drugs, promptly apologize, and
make a sincere effort to regain the patient’s trust.
DISCUSSION
Previous literature on medical errors has yet to
focus on inadvertent outcomes in drug sampling
with outdated drugs. Much more attention has been
traditionally garnered by wrong site surgery and
prescribing errors. Although these situations may
result in more severe consequences, the increased
frequency of outdated samples serves to bring this
issue to the forefront. The future literature should
further examine this type of medical error in an
attempt to spread awareness.
Drug expiry dates are rigorously calculated
based on determinants that account for the
half-life of ingredients and expected conditions of
storage. Outdated drugs may prove to have se-
verely altered chemical stabilities and biological
mechanisms of action. This can lead patients to
believe that they are adhering to effective treatment
when that might not be the case. Possible conse-
quences include an adverse reaction or failure to
achieve the desired therapeutic outcome. If the
physician is the party responsible for providing
outdated samples, then he or she should be ac-
countable for notifying the patient, promptly apol-
ogizing, and rectifying the error regardless of the
actual level of harm.
Commonly used dermatologic drugs are particu-
larly sensitive to light, temperature, and moisture,
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and such exposures can promote chemical processes
of degradation and loss of activity.1 Improper storage
also decreases the strength of dermatologic drugs. In
the scenario described, adverse effects from the
sample being outdated may be further compounded
by potential storage conditions that have aided in the
disruption of pharmacological stability. Fluorouracil
topical cream is especially sensitive as evidenced by
a recent manufacturing failure to guarantee stan-
dards of strength, quality, and purity due to inade-
quate conditions and inappropriate testing when
establishing expiry dates.2 The dermatologist can
assess neither the complete level of efficacy nor the
total degree of risk associated with the drug sample
in question.
To avoid the above scenario, dermatologists
should have a system in place to regularly monitor
the expiry dates of the drug samples in their inven-
tory. Ideally, a readily accessible document should
be created to record each of the individual dates, lot
numbers, and prescribed patients. If drug sampling is
to be continued, then dermatologists are obligated to
keep detailed logs to protect their patients from any
related harm. This process should be built to closely
resemble that of pharmacy dispensing. Current drug
sampling effectively bypasses the safety checkpoints
that pharmacies are required to have in place to limit
medication errors. Dermatologists should consider
complete implementation of an electronic record-
keeping system that is updated concurrently with the
intake and outtake of all samples. In addition,
recommendations for suitable storage should be
reviewed upon the receipt of all drug samples with
the corresponding conditions appropriately main-
tained in the clinic. These specific tasks are essential
to promoting proper patient protection and adher-
ence to clinical safety guidelines.
Root cause analysis is a crucial part of our
response when medical errors do unfortunately
occur. Dermatologists are responsible for investigat-
ing why there was an error in patient care, how the
event was allowed to occur in the current system,
and what can be done to further prevent this error in
the future. Regardless of how the medical error
occurred, the dermatologist should assure the pa-
tient that all is being done to fix the system and may
even expound on what changes are being imple-
mented to prevent this from happening again.
Using the four basic principles of autonomy, ben-
eficence, nonmaleficence, and justice alone as a
diagnostic toolmay lead to a failure on the physician’s
part to identify all of the applicable obligations owed
to thepatient. Tomaintain a healthypatient-physician
relationship, the dermatologist in this casemust fulfill
additional moral obligations related to the medical
error. The dermatologist has obligations to promptly
apologize and to regain the patient’s trust and confi-
dence. These actionswill help the patient understand
that the dermatologist is still working in the patient’s
best interests regardless of the error that was made.
Although some physicians may not willingly ad-
mit that they have made a medical error, open
expressions of regret and apologies are crucial pri-
mary steps to regaining patient trust. Attempts to
make amends and to secure the patient’s confidence
are significant in rebuilding future rapport. Since
2001, the University of Michigan Health System has
pioneered a policy of full disclosure for medical
errors with offers of compensation to patients. The
adoption of this program has decreased liability
claims, patient lawsuits, resolution time, and associ-
ated costs.3 In response to this study, we believe that
the cultures of medicine and health care should be
even more accepting of physician practices of
openly admitting mistakes and apologizing.
The disclosure of medical error is a cornerstone of
contemporary medical professionalism. In 2001,
The Joint Commission required medical disclosure
by hospitals and their staff. Subsequently, seven
states–Nevada, Florida, New Jersey, Pennsylvania,
Oregon, Vermont, and California–have since man-
dated the disclosure of unanticipated health out-
comes to patients. More than 30 states have also
enacted laws to protect information conveyed during
apologies and disclosures from being used in
malpractice lawsuits.4
ANALYSIS OF CASE SCENARIO
In this case, option A is incorrect because it
would be a gross mistake on the dermatologist’s
part to ignore thepotential for harm to thepatient.
Patients place their health in the hands of their
physicians, and this option would be an absolute
breach of both trust and confidence inherent in
the patient-physician relationship. Physicians
should consistently strive to act in their patients’
best interests, and any errors that compromise
their well-being should be addressed.
Option B is an example of responsibility
shifting between dermatologists and, therefore,
is incorrect. This particular action should not be
condoned in cases of medical error because
patient crises often do not receive the immediate
and proper attention that is warranted. Although
it is certainly appropriate for an inexperienced
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physician to seek counsel from a more experi-
enced colleague, it is ultimately the original
physician’s obligation to notify the patient and
rectify the error. Physicians must be accountable
for correcting their own mistakes, and they
have the personal responsibility to undertake
the healing of damaged patient-physician
relationships.
Although option C warns the patient in a
timely manner and offers an immediate re-
placement of the drug sample, nothing else is
done on the dermatologist’s part to further
rectify the medical error. At first glance, this
specious solution may appear to be correct
because it is responsive to the patient’s best
interests and prevents any avoidable future
harm. However, physicians must be aware of
moral obligations that go beyond the concerns
of beneficence and nonmaleficence relevant to
this case, which makes this option only par-
tially correct.
Option D not only notifies the patient of the
associated risks and attempts to correct the
mistake, but also goes further in fulfilling the
physician’s moral obligations to the patient in
dealing with a medical error. Therefore, this
option represents the best solution. The derma-
tologist shows concerns beyond the welfare of
the patient by acknowledging features critical to
the patient-physician relationship. The major
burdens of maintaining a healthy patient-
physician relationship continue to rest on the
shoulders of the physician.
The efficacy of dermatologic drugs can be
adversely affected by the length of time since
manufacture as well as by improper storage
conditions. If outdated drug samples have been
provided to patients, it remains the ethical respon-
sibility of the physician to correct this medical
error and to repair the patient-physician relation-
ship. In option D, the dermatologist recognizes
and fulfills her moral obligations to the patient.
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